Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:monoclonal_antibody
|
| gptkbp:administeredBy |
subcutaneous injection
|
| gptkbp:approvalYear |
2018
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
N02CD03
|
| gptkbp:brand |
gptkb:Aimovig
|
| gptkbp:CASNumber |
gptkb:1336880-97-7
|
| gptkbp:developedBy |
gptkb:Amgen
gptkb:Novartis |
| gptkbp:firstBook |
yes
|
| https://www.w3.org/2000/01/rdf-schema#label |
erenumab
|
| gptkbp:indication |
chronic migraine
episodic migraine |
| gptkbp:KEGGID |
D10913
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:macromoleculeType |
IgG2 monoclonal antibody
|
| gptkbp:mechanismOfAction |
CGRP receptor antagonist
|
| gptkbp:pregnancyCategory |
not assigned (US)
|
| gptkbp:PubChem_CID |
DB13950
|
| gptkbp:routeOfAdministration |
subcutaneous
|
| gptkbp:sideEffect |
constipation
injection site reaction muscle cramps |
| gptkbp:target |
calcitonin gene-related peptide receptor
|
| gptkbp:UNII |
8ZQ37L233D
|
| gptkbp:usedFor |
migraine prevention
|
| gptkbp:bfsParent |
gptkb:Aimovig
|
| gptkbp:bfsLayer |
7
|